Pharmocann Global Past Earnings Performance

Past criteria checks 0/6

Pharmocann Global has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 9.3% annually. Revenues have been declining at an average rate of 9.1% per year.

Key information

15.6%

Earnings growth rate

40.5%

EPS growth rate

Pharmaceuticals Industry Growth35.1%
Revenue growth rate-9.1%
Return on equity-4,587.4%
Net Margin-76.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence

Mar 30
The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence

Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?

Feb 04
Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?

Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Dec 31
Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come

Nov 26
The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come

Revenue & Expenses Breakdown

How Pharmocann Global makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TASE:PMCN-M Revenue, expenses and earnings (ILS Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2413-1080
31 Mar 2414-1080
31 Dec 2314-1080
30 Sep 2311-1260
30 Jun 2312-1871
31 Mar 2317-24101
31 Dec 2223-25131
30 Sep 2224-23121
30 Jun 2225-20131
31 Mar 2228-16151
31 Dec 2129-19151
30 Sep 2131-14151
30 Jun 2132-7151
31 Mar 21312131
31 Dec 20284131
30 Sep 20266111
30 Jun 20265101
31 Mar 2021-2591
31 Dec 1921-4661
30 Sep 1918-4660
30 Jun 1917-4640
31 Mar 1916-2040
31 Dec 1815630
31 Dec 1712230
31 Dec 169120

Quality Earnings: PMCN-M is currently unprofitable.

Growing Profit Margin: PMCN-M is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PMCN-M is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.

Accelerating Growth: Unable to compare PMCN-M's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PMCN-M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.1%).


Return on Equity

High ROE: PMCN-M has a negative Return on Equity (-4587.44%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:42
End of Day Share Price 2024/12/22 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmocann Global Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution